NASDAQ:LMNX - Luminex Stock Price, Price Target & More

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex announced a quarterly dividend on Friday, May 18th. Stockholders of record on Friday, June 22nd will be paid a dividend of $0.06 per share on Friday, July 13th. This represents a $0.24 annualized dividend and a dividend yield of 0.80%. The ex-dividend date is Thursday, June 21st. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) issued its earnings results on Monday, May, 7th. The medical instruments supplier reported $0.30 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.22 by $0.08. The medical instruments supplier earned $82.60 million during the quarter, compared to analyst estimates of $80.52 million. Luminex had a return on equity of 8.07% and a net margin of 10.60%. The firm's revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.28 earnings per share. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Luminex.

4 Wall Street analysts have issued 1-year target prices for Luminex's stock. Their predictions range from $21.00 to $26.00. On average, they anticipate Luminex's stock price to reach $23.00 in the next twelve months. View Analyst Ratings for Luminex.

Luminex saw a decline in short interest during the month of May. As of May 31st, there was short interest totalling 1,741,856 shares, a decline of 44.1% from the May 15th total of 3,113,587 shares. Based on an average daily trading volume, of 522,399 shares, the short-interest ratio is presently 3.3 days. Currently, 4.2% of the company's stock are sold short.

Some companies that are related to Luminex include Globus Medical (GMED), Penumbra (PEN), Haemonetics (HAE), Cantel Medical (CMD), NuVasive (NUVA), Novocure (NVCR), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS), Orthofix International (OFIX), OraSure Technologies (OSUR), Intersect ENT (XENT) and Atrion (ATRI).

Headlines about LMNX stock have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Luminex earned a coverage optimism score of 0.15 on Accern's scale. They also assigned news coverage about the medical instruments supplier an impact score of 46.46 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Luminex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.95%), Dimensional Fund Advisors LP (4.39%), Neuberger Berman Group LLC (2.60%), Millennium Management LLC (2.34%), Investment Management of Virginia LLC (2.21%) and Northern Trust Corp (2.15%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Neuberger Berman Group LLC, Alambic Investment Management L.P., Thomson Horstmann & Bryant Inc., Elk Creek Partners LLC, Blair William & Co. IL, American International Group Inc. and BNP Paribas Arbitrage SA. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Insider Buying and Selling for Luminex.

LMNX stock was bought by a variety of institutional investors in the last quarter, including Hancock Holding Co., DAFNA Capital Management LLC, Dimensional Fund Advisors LP, Millennium Management LLC, Tamarack Advisers LP, Federated Investors Inc. PA, BlackRock Inc. and Great Lakes Advisors LLC. Company insiders that have bought Luminex stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $30.12.

Luminex has a market capitalization of $1.34 billion and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]